The diagnosis and treatment of primary lateral sclerosis (PLS) centre around alleviating symptoms and preserving functionality. Explore further insights in this article to deepen your understanding of this topic.

PLS is a rare neurological condition affecting movement-controlling nerve cells in the brain. Treatment aims to manage symptoms and enhance quality of life through therapy and medication, emphasizing early intervention for optimal outcomes.

Although PLS remains an intriguing but infrequent neurological condition with uncertain underlying mechanisms, we invite you to explore more to gain insights into its diagnosis and treatment strategies. Keep reading to uncover additional information about this interesting disorder.

Introduction

Overview of primary lateral sclerosis (PLS)

Primary lateral sclerosis (PLS) is an uncommon condition characterized by progressive dysfunction of the upper motor neurons, without involvement of the lower motor neurons or a familial history suggestive of hereditary spastic paraplegia.  It represents a small proportion, around 1% to 4%, of all cases of motor neuron disease. ¹

PLS generally initiates in adulthood and distinguishes itself from other infrequent disorders impacting the nerve cells of young individuals. PLS manifests as a gradual progression over time, yet its prognosis remains challenging to anticipate due to its rarity and diagnostic intricacies. Individuals diagnosed with PLS typically have a life expectancy of at least a decade following symptom onset, with variations depending on factors such as age and overall health condition.² 

Diagnosis of primary lateral sclerosis 

Clinical evaluation and history

Overview of the latest agreement criteria for diagnosing primary lateral sclerosis ² :

1. Core principles:

• Individuals must be a minimum of 25 years of age
• Symptoms of progressive upper motor neuron (UMN) dysfunction should persist for a minimum of 2 years
• Signs of UMN dysfunction must be evident in at least two out of three regions: lower extremity, upper extremity, and bulbar
• Sensory symptoms not explained by another condition should be absent
• Active lower motor neuron (LMN) degeneration should not be present
• Any alternative diagnosis should be supported by UMN pathology identified through neuroimaging or biofluid testing, providing a plausible explanation for the clinical syndrome

2. Diagnostic certainty:

• Probable PLS: Absence of significant active LMN degeneration 2–4 years from symptom onset
• Definite PLS: Absence of significant active LMN degeneration for 4 or more years from symptom onset

Examination

To diagnose primary lateral sclerosis, doctors look for specific signs and symptoms that show problems with the upper motor neurons (UMN) in the brain. These symptoms need to last for at least 2 years and start after the age of 25. Doctors also check for UMN dysfunction in at least two out of three regions of the body. They rule out other possible causes like sensory issues or lower motor neuron (LMN) problems. They also make sure there's no different condition that could explain the symptoms, which they can see on scans or tests of body fluids. The certainty of the diagnosis can change over time. If there's no significant LMN degeneration 2–4 years after the symptoms start, it's called probable PLS. If there's still no significant LMN degeneration after 4 or more years, it's called definite PLS. Signs of UMN dysfunction include muscle stiffness, weakness, overactive reflexes, and problems with emotional control. Although some cases of PLS have genetic factors, doctors mainly rely on the symptoms they see rather than genetic tests, especially because PLS mostly happens without a clear family history.¹ 

Investigations play a crucial role in diagnosing Primary Lateral Sclerosis (PLS), as it is primarily diagnosed based on clinical observations. Unlike typical forms of Amyotrophic Lateral Sclerosis (ALS), PLS lacks specific biomarkers, making it susceptible to mimic disorders. MRI scans of the brain and spinal cord are essential to rule out structural, inflammatory, vascular, and metabolic issues. Electromyography (EMG) helps exclude lower motor neuron (LMN) involvement, while normal serum creatine kinase levels indicate minimal LMN damage. Cortical excitability tests and PET scans show similarities between ALS and PLS, suggesting common underlying mechanisms. Blood and cerebrospinal fluid (CSF) neurofilament levels, while elevated in ALS, may be less significant in PLS. Overall, a combination of biomarkers and imaging techniques may enhance the diagnostic process for PLS in the future.²

Differential diagnosis

When diagnosing primary lateral sclerosis, it is important to differentiate it from similar conditions. Hereditary spastic paraparesis (HSP) shares many symptoms with early-stage PLS, making it a common point of confusion. Both HSP and PLS are mostly diagnosed based on clinical symptoms, and some people thought to have HSP do not have a known genetic cause. Conditions that mimic PLS are uncommon, and detailed brain and spinal cord scans can usually rule them out. Other disorders, like amyotrophic lateral sclerosis and certain inflammatory or metabolic conditions, can also look like PLS but might have different features on scans or require specific tests for diagnosis. Additionally, infectious, structural, and vascular issues can sometimes present similarly to PLS, so doctors consider all possibilities based on each patient's symptoms.³

Treatment approaches for primary lateral sclerosis (PLS)

Symptoms

The symptoms associated with the core clinical syndrome of primary lateral sclerosis (PLS) exhibit consistent patterns in affected individuals. Typically, these symptoms commence around the age of 50, occurring earlier than non-familial amyotrophic lateral sclerosis (ALS) but later than hereditary spastic paraparesis (HSP). While some cases may manifest during childhood, they are often associated with other developmental or genetic disorders. PLS tends to affect more males than females and its onset is gradual, leading to delayed diagnosis in many cases. Symptoms commonly originate in the lower limbs, although a significant minority may initially present with speech difficulties and emotional changes, such as pseudobulbar affect. Dysphagia may also occur but is usually less severe than in ALS, and the need for breathing support is rare. Lower limb symptoms can manifest as balance problems or changes in gait, while sensory issues are not prominent. Spasticity and hyperreflexia are frequently observed during clinical examination. Although PLS can progress to involve the upper limbs, it seldom starts exclusively in this region. Bladder problems are prevalent, and while some cases may exhibit broader brain involvement or extrapyramidal features, cognitive impairment, particularly frontotemporal dementia, is less common compared to ALS. In rare cases, PLS may present with progressive weakness on one side of the body, resembling solitary sclerosis, but careful examination can help distinguish it from other conditions. These consistent clinical features collectively define the core clinical syndrome of PLS and aid in its diagnosis and management.³

Care and supportive services

Currently, there are no therapies available to prevent, halt, or reverse primary lateral sclerosis. The primary aim of managing primary lateral sclerosis is to alleviate symptoms and enhance functional abilities, given the absence of a cure:¹ 

1. Non-Medication Approaches: Non-medical strategies, including physical and occupational therapy, are employed to improve mobility and range of motion, thereby enhancing overall functional capacity.
2. Medication Options: Various medications such as baclofen, tizanidine, or valium are prescribed to address spasticity, a common symptom associated with PLS.
3. Advanced Treatment Modalities: In cases where oral medications cause undesirable side effects, advanced treatment options like intrathecal baclofen delivered via a pump may be considered to manage spasticity more effectively. 
4. Management of Excessive Oral Secretions: Excessive oral secretions, another common symptom, are managed using oral anticholinergic medications or botulinum toxin injections. 
5. Treatment for Pseudobulbar effect: Pseudobulbar affect, characterized by uncontrollable episodes of laughter or crying, may be treated with a combination of dextromethorphan and quinidine or tricyclic antidepressants.
6. Regular Evaluation and Monitoring: Continuous assessment through regular evaluations with physical and occupational therapy, coupled with appropriate medication management, is crucial for ensuring effective symptom control and overall management of PLS.

Prognosis and long-term management

In primary lateral sclerosis (PLS), the initial manifestation of symptoms primarily involves upper motor neurons, characterized by symptoms like muscle stiffness or spasticity, without accompanying signs of lower motor neuron involvement, such as muscle twitching or atrophy. However, the onset of symptoms indicative of lower motor neuron dysfunction can significantly influence the prognosis and progression of the disease. This transition often raises concerns about the potential evolution of PLS into amyotrophic lateral sclerosis (ALS), a more severe neurological condition characterized by the progressive degeneration of both upper and lower motor neurons. Diagnostic procedures like electromyography (EMG) are crucial in identifying these changes and assessing disease progression. The absence of lower motor neuron symptoms within four years typically suggests a more favourable prognosis, with patients maintaining pure upper motor neuron dysfunction and a normal lifespan. Nonetheless, the emergence of lower motor neuron symptoms, even after several years, may signify a more aggressive disease course or a transition to ALS. Understanding these nuances is essential in managing PLS and providing appropriate care to affected individuals.¹

Long-term management of PLS involves a multifaceted approach that integrates ongoing large-scale studies aimed at elucidating the genetic underpinnings, natural progression, and underlying mechanisms of the disease. Present treatment strategies predominantly revolve around supportive care, encompassing modalities such as physical therapy and pharmacological interventions to alleviate symptoms such as spasticity and pseudobulbar affect. As research into the pathophysiology of PLS continues to advance, there is optimism regarding the development of novel therapeutic interventions that are more precisely tailored to address the unique requirements of individuals affected by this condition.¹

Summary

Primary lateral sclerosis (PLS) is a rare condition characterized by slowly progressive upper motor neuron dysfunction, distinct from amyotrophic lateral sclerosis (ALS). Symptoms typically start in the lower limbs, with symmetrical spasticity being a consistent finding. Bulbar involvement is common, often accompanied by severe emotional reflex hypersensitivity. The presence of significant lower motor neuron involvement within 4 years suggests ALS. While PLS is disabling, it may not shorten life expectancy.

Individuals with PLS need tailored therapeutic approaches due to the condition's longer natural history compared to ALS. Addressing spasticity is a key unmet need, and PLS patients can serve as valuable comparators in biomarker research. Awareness among healthcare providers is crucial to reduce diagnostic delays.

FAQs

Is PLS better than ALS? 

Primary Lateral Sclerosis (PLS)  progresses more slowly than Amyotrophic Lateral Sclerosis (ALS) and is not usually fatal.

How is PSL diagnosed? 

Diagnosis involves blood tests, electrodiagnostic examinations, and magnetic resonance imaging (MRI) of the brain and spinal cord to assess nerve and muscle function.

Does PLS affect cognition?

PLS may lead to cognitive decline or behavioural changes alongside difficulties in daily activities such as swallowing and nutrition.